

Board of Directors Meeting in Public - Cover Sheet

Subject:	Board of Directors			Date: 23/11/2022		
Dropored Dv	IPC Board Assurance Framework					
Prepared By:	Carl Miller Deputy to the Chief Nurse and Sally Palmer Nurse Consultant IPC					
Approved By:	Phil Bolton Chief Nurse					
Presented By: Phil Bolton Chief Nurse						
Purpose						
To update the Board on our compliance with NHS				Approval		
England/Improvements Infection Prevention and Control			Assurance	Χ		
Board Assurance Framework				Update	Χ	
				Consider		
Strategic Objectives						
To provide	To promote and	To maximise the		To continuously		To achieve
outstanding	support health	potential of our	learn and improve		better value	
care	and wellbeing	workforce				
X	X					
Identify which principal risk this report relates to:						
PR1 Significant deterioration in standards of safety and care						X
PR2 Demand that overwhelms capacity						
PR3 Critical shortage of workforce capacity and capability						
PR4 Failure to achieve the Trust's financial strategy						
,	,					
innovation						
PR6 Working more closely with local health and care partners does not fully						
deliver the required benefits						
PR7 Major disruptive incident						
	· ·					
change						
Committees/groups where this item has been presented before						

Executive Summary

Patient Safety Committee

This board assurance framework has been completed to provide assurance of our infection control management of respiratory infections. The full document has been submitted to the reading room for review. The framework was updated on 26th September 2022 and has detailed 96 key lines of enquiry under 10 headings. It has previously been submitted to PSC and IPCC and been discussed in these forums.

The latest changes continue to include all respiratory viruses and have removed most of the dedicated Covid elements. There is a plan for the framework to be updated again in March 2023 to include all Infections.

Our compliance against this remains unchanged and there remain a number of elements of this framework that we cannot give full evidenced assurance on at this time. This includes the information required on some of the ventilation section and antimicrobial management section both of which we are awaiting further evidence from the relevant teams. This is currently being gathered. We have evidence for 88 key lines of enquiry and are outstanding information for 8.



Noting the plans to deliver the exceptions described Board is asked to the be updated and approved of the current